Driving Global Access to Comprehensive Genomic Profiling for all Patients with Cancer
Vision
The Precision Cancer Consortium (PCC) aims to make precision oncology and comprehensive genomic profiling the new normal
Mission
The PCC will foster collaboration to improve global patient access to comprehensive genomic profiling in routine care and clinical trials
Our Members
A Collaboration to Address Challenges Associated with Precision Oncology
Challenges that are ecosystem related cannot be solved by one stakeholder of the healthcare system alone. The PCC facilitates collaboration of pharma/biotech companies to address challenges regarding access, awareness, and research and development of comprehensive genomic testing for cancer patients globally
PCC Strategic Objectives
- Increase patient access to comprehensive genomic profiling (CGP) in both routine care and research, globally
- Educate stakeholders and increase awareness on how CGP can improve patient outcomes
- Address the challenges of implementing CGP in healthcare systems to improve equitable access to testing
Definition of ‘Comprehensive’
The PCC considers comprehensive genomic profiling (CGP) to include all genomic biomarkers necessary to support clinical decisions in terms of access to currently available targeted therapies and clinical trial enrolment for a given cancer indication
Rationale for Consortium Approach
Challenges that are ecosystem related cannot be solved by one stakeholder of the healthcare system alone. The PCC facilitates collaboration of pharma/biotech companies to address challenges regarding access, awareness, and research and development of comprehensive genomic testing for cancer patients globally
